Endpoints News· Reynald Castaneda·· 2 天前AI 评分60
BioNTech 与 DualityBio 在乳腺癌结果有限后考虑 HER2 ADC 后续方案
BioNTech, DualityBio ponder next steps for HER2 ADC after 'modest' breast cancer results
AI 导读
BioNTech 与 DualityBio 正在考虑 trastuzumab pamirtecan 在部分乳腺癌患者中的下一步方案，该 HER2 ADC 在试验中取得统计学显著结果，但原文以付费墙截断，未披露具体数据。
正文 · 原文
BioNTech and DualityBio are mulling what to do next with trastuzumab pamirtecan in certain breast cancer patients after the antibody-drug conjugate delivered a “statistically significant …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源：Endpoints News · endpoints.news